Terms: = Ovarian cancer AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1 AND Treatment
17 results:
1. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial cancer.
Vergote I; Pérez-Fidalgo JA; Hamilton EP; Valabrega G; Van Gorp T; Sehouli J; Cibula D; Levy T; Welch S; Richardson DL; Guerra EM; Scambia G; Henry S; Wimberger P; Miller DS; Klat J; Martínez-Garcia J; Raspagliesi F; Pothuri B; Romero I; Bergamini A; Slomovitz B; Schochter F; Høgdall E; Fariñas-Madrid L; Monk BJ; Michel D; Kauffman MG; Shacham S; Mirza MR; Makker V;
J Clin Oncol; 2023 Dec; 41(35):5400-5410. PubMed ID: 37669480
[TBL] [Abstract] [Full Text] [Related]
2. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
Westin SN; Fu S; Tsimberidou A; Piha-Paul S; Akhmedzhanov F; Yilmaz B; McQuinn L; Brink AL; Gong J; Leung CH; Lin H; Hong DS; Pant S; Carter B; Jazaeri A; Gershenson D; Sood AK; Coleman RL; Shah J; Meric-Bernstam F; Naing A
Gynecol Oncol; 2023 Jan; 168():76-82. PubMed ID: 36423446
[TBL] [Abstract] [Full Text] [Related]
3. The efficacy of selinexor (KPT-330), an xpo1 inhibitor, on non-hematologic cancers: a comprehensive review.
Landes JR; Moore SA; Bartley BR; Doan HQ; Rady PL; Tyring SK
J Cancer Res Clin Oncol; 2023 May; 149(5):2139-2155. PubMed ID: 35941226
[TBL] [Abstract] [Full Text] [Related]
4. Enhancement of MDM2 inhibitory effects through blocking nuclear export mechanisms in ovarian cancer cells.
Alzahrani A; Natarajan U; Rathinavelu A
Cancer Genet; 2022 Aug; 266-267():57-68. PubMed ID: 35785714
[TBL] [Abstract] [Full Text] [Related]
5. Rational Combination of crm1 Inhibitor Selinexor and Olaparib Shows Synergy in ovarian cancer Cell Lines and Mouse Models.
Handley KF; Rodriguez-Aguayo C; Ma S; Stur E; Joseph R; Bayraktar E; Dasari SK; Nguyen N; Powell RT; Sobieski M; Ivan C; Kim M; Umamaheswaran S; Glassman D; Wen Y; Amero P; Stephan C; Coleman RL; Landesman Y; Westin SN; Ram PT; Sood AK
Mol Cancer Ther; 2021 Dec; 20(12):2352-2361. PubMed ID: 34583979
[TBL] [Abstract] [Full Text] [Related]
6. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
Thein KZ; Piha-Paul SA; Tsimberidou A; Karp DD; Janku F; Zarifa A; Shah J; Milton DR; Bean S; McQuinn L; Gong J; Colen R; Carter BW; Subbiah V; Ogbonna DC; Pant S; Meric-Bernstam F; Naing A
Invest New Drugs; 2021 Oct; 39(5):1357-1365. PubMed ID: 33909232
[TBL] [Abstract] [Full Text] [Related]
7. NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to xpo1 Inhibitors.
Miyake TM; Pradeep S; Bayraktar E; Stur E; Handley KF; Wu SY; Rodriguez-Aguayo C; Lee JS; Lopez-Berestein G; Coleman RL; Sood AK
Mol Cancer Ther; 2020 Aug; 19(8):1727-1735. PubMed ID: 32499298
[TBL] [Abstract] [Full Text] [Related]
8. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.
Vergote IB; Lund B; Peen U; Umajuridze Z; Mau-Sorensen M; Kranich A; Van Nieuwenhuysen E; Haslund C; Nottrup T; Han SN; Concin N; Unger TJ; Chai Y; Au N; Rashal T; Joshi A; Crochiere M; Landesman Y; Shah J; Shacham S; Kauffman M; Mirza MR
Gynecol Oncol; 2020 Feb; 156(2):308-314. PubMed ID: 31822399
[TBL] [Abstract] [Full Text] [Related]
9. Inhibition of crm1 activity sensitizes endometrial and ovarian cell lines to TRAIL-induced cell death.
Fabi F; Adam P; Vincent K; Demontigny F; Parent S; Joncas FH; Asselin E
Cell Commun Signal; 2018 Jul; 16(1):39. PubMed ID: 29973205
[TBL] [Abstract] [Full Text] [Related]
10. FoxO-1 contributes to the efficacy of the combination of the xpo1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
[TBL] [Abstract] [Full Text] [Related]
11. Phenethyl isothiocyanate suppresses the metastasis of ovarian cancer associated with the inhibition of crm1-mediated nuclear export and mTOR-STAT3 pathway.
Shao WY; Yang YL; Yan H; Huang Q; Liu KJ; Zhang S
Cancer Biol Ther; 2017 Jan; 18(1):26-35. PubMed ID: 27981892
[TBL] [Abstract] [Full Text] [Related]
12. Inhibition of the Nuclear Export Receptor xpo1 as a Therapeutic Target for Platinum-Resistant ovarian cancer.
Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
[No Abstract] [Full Text] [Related]
13. Novel reversible selective inhibitor of crm1 for targeted therapy in ovarian cancer.
Liu X; Chong Y; Liu H; Han Y; Niu M
J Ovarian Res; 2015 Jun; 8():35. PubMed ID: 26055813
[TBL] [Abstract] [Full Text] [Related]
14. xpo1/crm1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.
Miyake T; Pradeep S; Wu SY; Rupaimoole R; Zand B; Wen Y; Gharpure KM; Nagaraja AS; Hu W; Cho MS; Dalton HJ; Previs RA; Taylor ML; Hisamatsu T; Kang Y; Liu T; Shacham S; McCauley D; Hawke DH; Wiktorowicz JE; Coleman RL; Sood AK
Clin Cancer Res; 2015 Jul; 21(14):3286-97. PubMed ID: 25878333
[TBL] [Abstract] [Full Text] [Related]
15. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
[TBL] [Abstract] [Full Text] [Related]
16. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/xpo1 is a prognostic factor in human ovarian cancer.
Noske A; Weichert W; Niesporek S; Röske A; Buckendahl AC; Koch I; Sehouli J; Dietel M; Denkert C
Cancer; 2008 Apr; 112(8):1733-43. PubMed ID: 18306389
[TBL] [Abstract] [Full Text] [Related]
17. Identification of a functional nuclear export sequence in BRCA1.
Rodríguez JA; Henderson BR
J Biol Chem; 2000 Dec; 275(49):38589-96. PubMed ID: 10991937
[TBL] [Abstract] [Full Text] [Related]
